دورية أكاديمية
Effectiveness and safety of low-dose interferon alpha-2a treatment in Behçet’s Syndrome with refractory vascular or neurological involvement: a case series
| العنوان: | Effectiveness and safety of low-dose interferon alpha-2a treatment in Behçet’s Syndrome with refractory vascular or neurological involvement: a case series |
|---|---|
| المؤلفون: | Luxi Sun, Yunxia Hou, Lifan Zhang, JinJing Liu, Lu Li, Zhimian Wang, Xin Yu, Menghao Zhang, Xiaoqing Liu, Yan Zhao, Wenjie Zheng |
| المصدر: | Therapeutic Advances in Chronic Disease, Vol 13 (2022) |
| بيانات النشر: | SAGE Publishing, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Therapeutics. Pharmacology |
| مصطلحات موضوعية: | Therapeutics. Pharmacology, RM1-950 |
| الوصف: | Objective: The aim of this study was to evaluate the effectiveness and safety of low-dose interferon alpha-2a (IFNα2a) in Behçet’s syndrome (BS) patients with refractory vascular/cardiac or neurological involvement. Methods: In this retrospective cohort study, we consecutively included 25 BS patients with refractory vascular/cardiac ( n = 16) or neurological involvement ( n = 9) who received IFNα2a treatment in our center between June 2018 and September 2021. The low-dose IFNα2a (3 million IU, every other day) was used as an add-on treatment with the continuation of glucocorticoids (GCs) and immunosuppressants. Results: In total, 25 patients (20 males, 5 females) with a mean age of 31.92 ± 9.25 years were included. IFNα2a was administered for BS patients with refractory vascular/cardiac involvement ( n = 16) and neurological involvement ( n = 9). Before the initiation of IFNα2a, patients had insufficient response or intolerance to conventional therapies. After a median follow-up of 23 [interquartile range (IQR), 11–30] months, all patients achieved clinical improvement. The Behçet’s disease Current Activity Form (BDCAF) score improved significantly (5 versus 0, median, p 0.05). Decrease in erythrocyte sedimentation rate [ESR; 24 (IQR, 12–43.5) versus 5 (IQR, 2.75–10.5) mm/h, p = 0.0001] and C-reactive protein [CRP; 6.64 (IQR, 3.67–19.82) versus 1.24 (IQR, 0.24–3.12) mg/liter, p |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2040-6231 20406223 |
| Relation: | https://doaj.org/toc/2040-6231 |
| DOI: | 10.1177/20406223221111285 |
| URL الوصول: | https://doaj.org/article/58a53662accd4a698c1217e5f24ff171 |
| رقم الأكسشن: | edsdoj.58a53662accd4a698c1217e5f24ff171 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 20406231 20406223 |
|---|---|
| DOI: | 10.1177/20406223221111285 |